Filing Details
- Accession Number:
- 0001209191-20-054216
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-10-07 18:42:36
- Reporting Period:
- 2020-10-05
- Accepted Time:
- 2020-10-07 18:42:36
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1769804 | Augmedix Inc. | NONE | Blank Checks (6770) | 833299164 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1827312 | Mckesson Ventures, Llc | One Post Street San Francisco CA 94104 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-10-05 | 3,268,440 | $0.00 | 3,268,440 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2020-10-05 | 666,666 | $3.00 | 3,935,106 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Warrant (right to buy) | Acquisiton | 2020-10-05 | 303,893 | $0.00 | 303,893 | $2.88 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 303,893 | 2029-09-02 | No | 4 | A | Direct |
Footnotes
- On October 5, 2020, the Issuer's wholly-owned subsidiary, August Acquisition Corp. ("Acquisition Sub"), merged with and into Augmedix, Inc., a privately held Delaware corporation ("Augmedix"). Pursuant to this transaction (the "Merger"), Augmedix was the surviving corporation and became the Issuer's wholly owned subsidiary. All of the outstanding shares of stock of Augmedix held by accredited investors were converted into shares of the Issuer's common stock. All of the outstanding warrants, options and stock appreciation rights of Augmedix were assumed by the Issuer.
- These securities are held of record by McKesson Ventures LLC ("McKesson"). Jennifer M. Carter, a member of the Issuer's board of directors, isan executive vice president and chief strategy and business development officer at McKesson. As a result, McKesson is a director by deputization for Section 16 purposes.
- The warrants are fully vested and exerciseable.
Billionaire Hedge Funds
